Jason Zemansky is a vice president in Equity Research covering SMid Cap Biotechnology. Previously, he was a vice president at Barclays helping cover Large Cap Biotech and Pharma after starting his career in equity research at SVB Leerink. Prior to that, he worked as a consultant for Arthur D. Little (strategy) and IQVIA (pharma pricing and market access). He earned his Ph.D in Molecular and Cell Biology from the University of California, Berkeley, after receiving his AB in Molecular Biology from Princeton. He is based in New York.